Northern Trust’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-93,933
| Closed | -$141K | – | 4635 |
|
|
2023
Q1 | $141K | Buy |
93,933
+7,441
| +9% | +$10K | ﹤0.01% | 3980 |
|
|
2022
Q4 | $86.4K | Sell |
86,492
-3,321
| -4% | -$4.48K | ﹤0.01% | 4138 |
|
|
2022
Q3 | $161K | Buy |
89,813
+3,876
| +5% | +$11.2K | ﹤0.01% | 3965 |
|
|
2022
Q2 | $249K | Sell |
85,937
-201,314
| -70% | -$497K | ﹤0.01% | 3810 |
|
|
2022
Q1 | $793K | Sell |
287,251
-26,920
| -9% | -$84.7K | ﹤0.01% | 3540 |
|
|
2021
Q4 | $1.46M | Sell |
314,171
-10,139
| -3% | -$63.4K | ﹤0.01% | 3382 |
|
|
2021
Q3 | $2.76M | Sell |
324,310
-6,853
| -2% | -$96.8K | ﹤0.01% | 3105 |
|
|
2021
Q2 | $5.43M | Buy |
331,163
+1,738
| +0.5% | +$35.1K | ﹤0.01% | 2793 |
|
|
2021
Q1 | $7.27M | Sell |
329,425
-6,965
| -2% | -$190K | ﹤0.01% | 2504 |
|
|
2020
Q4 | $10.4M | Sell |
336,390
-6,897
| -2% | -$174K | ﹤0.01% | 2221 |
|
|
2020
Q3 | $6.97M | Buy |
343,287
+88,283
| +35% | +$1.55M | ﹤0.01% | 2326 |
|
|
2020
Q2 | $3.92M | Buy |
255,004
+101,151
| +66% | +$1.17M | ﹤0.01% | 2663 |
|
|
2020
Q1 | $1.19M | Buy |
153,853
+6,272
| +4% | +$76.8K | ﹤0.01% | 3139 |
|
|
2019
Q4 | $2.11M | Buy |
147,581
+7,410
| +5% | +$115K | ﹤0.01% | 3107 |
|
|
2019
Q3 | $2.11M | Buy |
+140,171
| New | +$2.18M | ﹤0.01% | 3077 |
|
Northern Trust's TCRR Position: Q2 2023 in Review
Northern Trust sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 93,933 shares — an estimated $141K sold.
Northern Trust first reported a position in TCRR in Q3 2019 and held it in 15 quarters. The position peaked at $10.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Northern Trust reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Northern Trust sold 93,933 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $141K.
- Northern Trust first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Northern Trust's TCR2 Therapeutics Inc. Common Stock position peaked at $10.4M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.